Eli Lilly vs Novo Nordisk: Obesity Drug Race Heats Up
Q1 2026 results from Eli Lilly and Novo Nordisk reveal a widening gap in the obesity drug race. Lilly grew revenue 55.5% and raised guidance, while Novo posted a 4% adjusted sales decline and announced 9,000 job cuts.
Key Numbers
According to 24/7 Wall St., Q1 2026 results from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) show a clear divergence in the GLP-1 obesity drug race. Eli Lilly reported 55.5% revenue growth and raised its full-year guidance, while Novo Nordisk posted a 4% decline in adjusted sales (at constant currency) and announced plans to cut 9,000 jobs.
Key Financial Results
| Company | Revenue (YoY) | Net Income | Notes |
|---|---|---|---|
| Eli Lilly | +55.5% | N/A | Raised annual guidance |
| Novo Nordisk | -4% (adjusted) | N/A | Cutting 9,000 jobs |
Highlights from the Reports
Both companies called obesity the "prize," but their quarterly results tell very different stories. Eli Lilly is benefiting from the success of its Mounjaro/Zepbound drugs, while Novo Nordisk faces competitive pressure from next-generation therapies.
Guidance
Eli Lilly raised its full-year revenue guidance, signaling confidence in continued growth. Novo Nordisk did not provide updated guidance.
Stock Impact
The report did not explicitly mention stock reactions, but Eli Lilly's results are likely to support its share price (LLY), while Novo Nordisk's results may pressure its stock (NVO).
What This Means for Investors
The results show Eli Lilly's near-term dominance, but the obesity drug market is still rapidly evolving. Novo Nordisk's pipeline could shift the balance. Investors should monitor both companies closely.
Frequently Asked Questions
Found this useful? Share it